Neuronal Intermediate Filament Inclusion Bodies In Neurodegeneration is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuronal intermediate filament inclusion bodies are pathological protein aggregates composed of neuronal intermediate filament proteins that accumulate in various neurodegenerative diseases. These inclusions represent a hallmark of several proteinopathies affecting the nervous system.
- NF-L (Light): 61 kDa subunit
- NF-M (Medium): 95 kDa subunit
- NF-H (Heavy): 200 kDa subunit
- α-Internexin: 66 kDa neuronal IF
- Vimentin: Developmental expression
- Peripherin: Peripheral nervous system
- Synemin: Cytoskeletal anchor
- Location: Axonal swellings
- Composition: NF accumulation
- Disease association: ALS, HD
¶ Lewy Body-Like Inclusions
- **α-synuclein co-localization
- **Parkinsonian syndromes
- **Multiple system atrophy
- Huntington disease: neuronal intranuclear inclusions
- Spinocerebellar ataxias: cytoplasmic inclusions
- Motor neuron disease: axonal spheroids
- Hyperphosphorylation: Prevents transport
- Kinases involved: GSK3β, CDK5, MAPK
- Phospho-epitopes: PHF-tau, NF-H
- Post-translational modifications: Ubiquitination
- Proteostasis failure: Autophagy dysfunction
- Seeding propagation: Prion-like spread
- NF spheroids: Motor neuron axons
- TDP-43 co-aggregation: Most cases
- SOD1 mutations: NF disruption
- Nuclear inclusions: Mutant huntingtin
- NF-L reduction: Early marker
- Dendritic abnormalities
- NF phosphorylation: Lewy bodies
- Axonal degeneration: Early event
- Biomarker potential: CSF NF-L
- Kinase inhibitors: Reduce phosphorylation
- Autophagy enhancers: Clear aggregates
- Gene therapy: IF expression modulation
- CSF neurofilament: Disease progression
- Blood NfL: Biomarker utility
- Imaging: PET ligands
The study of Neuronal Intermediate Filament Inclusion Bodies In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lee et al., Neurofilament aggregates in neurodegenerative disease (2019)
- Peled et al., Neurofilament light chain as biomarker (2021)
- Al-Chalabi & Powell, Neurofilament markers in ALS (2020)